Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc Raises FY 2012 Guidance


Wednesday, 25 Jul 2012 06:30am EDT 

Alexion Pharmaceuticals Inc announced that it is raising fiscal 2012 revenue guidance from the previous range of $1.065 to $1.085 billion now to the higher range of $1.110 to $1.125 billion. Guidance for fiscal 2012 non-GAAP earnings per share (EPS) is being raised, from the previous range of $1.65 to $1.75 per share, now to the higher range of $1.78 to $1.88 per share for the year. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $1.53 for fiscal 2012. 

Company Quote

163.21
0.32 +0.20%
11 Jul 2014